Enter your email address
Submit
Write your message
Volume 13, Issue 2 (8-2023)
cmja 2023, 13(2): 1-13 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Taheri F, Salemi Z. The study of the effect of biocanin A (a type of isoflavone) on serum levels of tumor necrosis factor alpha, interferon gamma and malondialdehyde and glutathione levels in pancreatic tissue of streptozotocin-induced diabetic rats. cmja 2023; 13 (2) :1-13
URL: http://cmja.arakmu.ac.ir/article-1-939-en.html
URL: http://cmja.arakmu.ac.ir/article-1-939-en.html
1- Master of Clinical Biochemistry, Arak University of Medical Sciences, Arak, Iran
2- Faculty of Clinical Biochemistry, Arak University of Medical Sciences, Arak, Iran ,zsalemi@arakmu.ac.ir
2- Faculty of Clinical Biochemistry, Arak University of Medical Sciences, Arak, Iran ,
Abstract: (1071 Views)
Introduction: BiochaninA (BCA) is of interest due to its antioxidant and anti-inflammatory effects.Oxidative stress and inflammation are key pathways in the development and progression of T1DM.The aim of this study is to determine the effect of biochaninA on the serum levels ofTNF-a, IFN-y,as well as the levels of GSH and MDA in the pancreas of rats infected with T1DM with streptozotocin.
Methods: 28 male Wistar rats were randomly divided into 4groups of 7each.A healthy control group received DMSO,the solvent of biochaninA.The rest of them were subjected to peritoneal-injection of streptozocin at the rate of 55mg/kg.One group was selected as a diabetic control(the second group)that only received DMSO,and the other two groups were treated with biochaninA at the rate of 10mg/Kg(the third group)and 15mg/Kg(the fourth group)for 6weeks.At the end,blood was collected from the heart and the parameters of TNF-a, IFN-y and FBS were measured in the serum.Then GSH and MDA factors were measured in the homogenized pancreatic tissue.
Results: The reduction of blood glucose and MDA was significant in treatment groups.GSH increased significantly with treatment.The reduction of TNF-a was significant only in the fourth group,but the reduction of IFN-y wasn't significant in any treatment group(P<0.05).
Conclusions: BiochaninA treatment is effective in controlling hyperglycemia.By increasing the level of GSH and decreasing MDA,this combination is important in improving the redox conditions in the pancreas,and by reducing the serum level of TNF-a,it improves the inflammatory conditions caused by diabetes and helps to reduce complications. No significant difference was observed between treatment doses.
Methods: 28 male Wistar rats were randomly divided into 4groups of 7each.A healthy control group received DMSO,the solvent of biochaninA.The rest of them were subjected to peritoneal-injection of streptozocin at the rate of 55mg/kg.One group was selected as a diabetic control(the second group)that only received DMSO,and the other two groups were treated with biochaninA at the rate of 10mg/Kg(the third group)and 15mg/Kg(the fourth group)for 6weeks.At the end,blood was collected from the heart and the parameters of TNF-a, IFN-y and FBS were measured in the serum.Then GSH and MDA factors were measured in the homogenized pancreatic tissue.
Results: The reduction of blood glucose and MDA was significant in treatment groups.GSH increased significantly with treatment.The reduction of TNF-a was significant only in the fourth group,but the reduction of IFN-y wasn't significant in any treatment group(P<0.05).
Conclusions: BiochaninA treatment is effective in controlling hyperglycemia.By increasing the level of GSH and decreasing MDA,this combination is important in improving the redox conditions in the pancreas,and by reducing the serum level of TNF-a,it improves the inflammatory conditions caused by diabetes and helps to reduce complications. No significant difference was observed between treatment doses.
Type of Study: Research |
Subject:
Other cases
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Contact Information
Complementary Medicine Journal
Arak University of Medical Sciences, Sardasht, Arak, Iran.
Journal Tel: +98 86 34173524
Email: journalcmjaarakmu.ac.ir
